AG003OJU

59803-98-4 | 5-​Bromo-​6-​(2-​imidazolin-​2-​ylamino)​quinoxaline

AG003OJU

SDS

COA

Price

$0.00

WARNING This product is not for human or veterinary use.

CAS Number	59803-98-4
Catalog Number	AG003OJU(AGN-PC-07A1SA)
Chemical Name	5-​Bromo-​6-​(2-​imidazolin-​2-​ylamino)​quinoxaline
IUPAC Name	5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine
InChI	InChI=1S/C11H10BrN5/c12-9-7(17-11-15-5-6-16-11)1-2-8-10(9)14-4-3-13-8/h1-4H,5-6H2,(H2,15,16,17)
InChI Key	XYLJNLCSTIOKRM-UHFFFAOYSA-N
MDL Number	MFCD00153878
Molecular Formula	C11H10BrN5
Molecular Weight	292.1346
NSC Number	318825
SMILES	BrC1=C2N=CC=NC2=CC=C1NC3=NCCN3
UNII	E6GNX3HHTE
Synonyms	5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline D-tartrate, 5-bromo-6-(imidazolidinylideneamino)quinoxaline, 5-bromo-6-(imidazolin-2-ylamino)quinoxaline, AGN 190342, AGN-190342, AGN190342, Alphagan, Alphagan P, brimonidine, brimonidine Purite, brimonidine tartrate, brimonidine tartrate (1:1), brimonidine tartrate (1:1), (S-(R*,R*))-isomer, brimonidine tartrate, (R-(R*,R*))-isomer, bromoxidine, mirvaso, Ratio Brimonidine, ratio-Brimonidine, Sanrosa, UK 14,304, UK 14,304 18, UK 14,304-18, UK 14,30418, UK 14,308, UK 14304, UK 14308, UK-14,304-18, UK-14,308, UK-14304, UK14,30418, UK14,308, UK14304, brimonidine, 59803-98-4, Bromoxidine, UK 14,304, 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine, UK-14304, 5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline, AGN 190342, UNII-E6GNX3HHTE, Brimonidine [INN:BAN], UK 14304, C11H10BrN5, MLS000069370, 6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-, E6GNX3HHTE, CHEMBL844, AGN-190342, BRN 0751629, SMR000058355, CHEBI:3175, LK 14304-18, Brimonidine, 98%, MFCD00153878, NCGC00016069-09, AK-35795, EN300-50880, DSSTox_CID_25221, DSSTox_RID_80758, DSSTox_GSID_45221, 5-Bromo-N-(2-imidazolin-2-yl)-6-quinoxalinamine, [3H]brimonidine, CAS-59803-98-4, SR-01000000023, brimonidina, brimonidinum, Brimonidine (INN), UK14304, Tocris-0425, [3H]-UK14304, UK 14308, Opera_ID_612, Lopac-U-104, UK-14,308, 5-bromo-6-(imidazolidinylideneamino)quinoxaline, UK 14,304-18, UK-14,304-18, AC1L1DO5, AC1Q24IC, AC1Q26LW, cid_2435, Lopac0_001216, SCHEMBL24670, GTPL520, MLS001076349, ARONIS24406, BIDD:GT0649, GTPL5386, DTXSID3045221, BDBM34572, CTK5B0525, XYLJNLCSTIOKRM-UHFFFAOYSA-N, 5-brom-n-(4,5-dihydro-1h-imidazol-2-yl)chinoxalin-6-amin, HMS3259P09, HMS3263D14, HMS3266O03, HMS3675K05, HY-B0659, KS-00000F2V, KS-000048KL, ZX-AS004769, Tox21_110299, Tox21_501216, AC-162, ANW-59812, NSC318825, PDSP1_000640, PDSP2_000635, SBB080815, ZINC21303210, AKOS005267239, IMED608142799, Tox21_110299_1, AN-6804, CCG-205290, CS-2892, DB00484, GS-3236, LP01216, MCULE-4542695850, NC00638, NSC-318825, TRA0032007, MRF-0000657, NCGC00016069-01, NCGC00016069-02, NCGC00016069-03, NCGC00016069-04, NCGC00016069-05, NCGC00016069-06, NCGC00016069-07, NCGC00016069-08, NCGC00016069-10, NCGC00016069-11, NCGC00016069-12, NCGC00016069-13, NCGC00023468-02, NCGC00023468-04, NCGC00023468-05, NCGC00023468-06, NCGC00023468-07, NCGC00261901-01, AJ-78420, BC215787, CC-25204, CJ-16916, CPD000058355, SAM002548958, UK14,304, LS-142950, ST2406733, TC-148557, B4132, EU-0101216, FT-0082636, FT-0630717, FT-0650586, UK 14304-18, C07886, D07540, 5-bromo-6-(2-imidazolidinylidenamino)quinoxaline, 5-bromo-6-(2-imidazolin-2-ylamino) quinoxaline, 5-Bromo-6-(2-imidazolin-2-ylamino)-quinoxaline, 6-Quinoxalinamine,5-dihydro-1H-imidazol-2-yl)-, (5-bromoquinoxalin-6-yl)-2-imidazolin-2-ylamine, 803B984, A832477, C-18323, L000615, SR-01000000023-2, SR-01000000023-4, BRD-K68264559-001-10-0, Z802671510, 6-Quinoxalinamine,5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-, (5-Bromo-quinoxalin-6-yl)-(4,5-dihydro-1H-imidazol-2-yl)-amine, 5-bromanyl-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine, 6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)- (9CI), mirvaso, Alphagan, Alphagan P, Sanrosa, Lumify, BRIMONIDINE TARTRATE, ratio-Brimonidine, Ratio Brimonidine, brimonidine Purite, D03ACG, D0AE3X, D0GD9D, brimonidine tartrate (1:1), 5-bromo-6-(imidazolin-2-ylamino)quinoxaline, C11-H10-Br-N5, CID2435, AGN190342, AR-1G7332, Allergan brand of brimonidine tartrate, Ratiopharm brand of brimonidine tartrate, UK14,308, Brimonidine (bioerodible, extended release), brimonidine tartrate, (R-(R*,R*))-isomer, Pharm-Allergan brand of brimonidine tartrate, UK 14,308, 2436B, U-104, UK14,30418, UK 14,30418, UK 14,304 18, C015620, brimonidine tartrate (1:1), (S-(R*,R*))-isomer, D000068438, 5-bromo-6-(2-imidazolin-2-ylamino)quinoxaline d-tartrate, Brimonidine base/5-Bromo-6-(imidazolin-2-ylamino)quinoxaline, 6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1), 70359-46-5, 7268-58-8, 79570-19-7,

Complexity	308
Compound Is Canonicalized	Yes
Covalently-Bonded Unit Count	1
Defined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Exact Mass	291.012g/mol
Formal Charge	0
Heavy Atom Count	17
Hydrogen Bond Acceptor Count	3
Hydrogen Bond Donor Count	2
Isotope Atom Count	0
Molecular Weight	292.14g/mol
Monoisotopic Mass	291.012g/mol
Rotatable Bond Count	2
Topological Polar Surface Area	62.2A^2
Undefined Atom Stereocenter Count	0
Undefined Bond Stereocenter Count	0
XLogP3	0.6

GHS Hazard and Precautionary Statements

Symbol:
Hazard statements	H317-H319
Precuationary statements	P280-P305+P351+P338
Siginal words

Certificate of Analysis

Lot Number